Solana Daytoni is a science writer, editor at Works in Progress magazine, and host of the Hard Drugs podcast focused on medical innovation. She previously worked at Our World in Data and has a background in scientific research before transitioning to science journalism and communication.

The conversation explores systemic problems in medical research and drug development, from data bias and publication incentives to clinical trial inefficiencies. Daytoni discusses why promising treatments take a decade to reach patients, how research bias affects global health understanding, and practical solutions for accelerating medical breakthroughs.

Key topics include the mouse-to-human translation problem in medical research, data collection bias highlighted in The Weirdest People In The World, revolutionary long-acting drug technologies, and structural reforms needed to improve scientific collaboration and clinical trial efficiency.

The Mouse Problem: Why Animal Research Fails Humans

Medical research heavily relies on animal testing due to path dependency and unwillingness to subject humans to experimental treatments, but fundamental biological differences mean we may be missing breakthroughs that work in humans but not animals.

"If you tried to test out chocolate in dogs, you would obviously get a very different result than you would if you tested it out on humans" - Solana, illustrating how species differences invalidate many research findings.

Global Health Data Crisis and Research Bias

Most health data comes from rich countries and gets extrapolated to estimate disease prevalence in places like India and Nigeria, creating massive blind spots in global health understanding.

The Weirdest People In The World demonstrates how 85% of psychology research is conducted on Western populations while ignoring 85% of the world, a bias that extends across scientific disciplines including medicine.

Even when data exists, it's often incomparable - surveys in one place versus medical records elsewhere, with hospital patients in India not representing the general population.

Scientific Gatekeepers and the Matthew Effect

The Matthew effect in science means successful researchers get more opportunities, disadvantaging newcomers and different perspectives while creating path dependency in research directions.

Pierre Azoulet found that "publications and citations increased from a lab once the lead scientists had died," confirming Max Planck's observation that science advances one funeral at a time.

Current academic structure expects scientists to be "all-star scientists who can do everything" - research, coding, writing, networking - which significantly slows progress compared to division of labor approaches.

Revolutionary Long-Acting Drug Technologies

New HIV prevention drugs require one injection every six months with nearly 100% efficacy, more effective than daily pills because people forget to take daily medication.

siRNA drugs can silence specific genes responsible for diseases, with new cholesterol drugs reducing levels by 60-70% with effects lasting 4-6 months from a single injection.

A new drug reduces lipoprotein A by 95% or more by silencing the specific gene that produces this type of cholesterol, representing a major breakthrough in cardiovascular medicine.

These drugs avoid digestive side effects because they're injected into muscle rather than taken orally, but pricing models for one-time treatments costing potentially $10,000 remain unsolved.

Clinical Trial Bottlenecks and Solutions

"There are medical breakthroughs in the pipeline right now that work, that won't get to patients for another decade from now" due to clinical trial inefficiencies, not scientific limitations.

The malaria vaccine approved three years ago was actually developed in the 1990s but took decades to reach patients due to funding challenges and lack of commercial incentives for diseases affecting the poor.

Clinical trials could test five drugs simultaneously versus placebo instead of one at a time, dramatically improving efficiency, as demonstrated by the Recovery trial during COVID that tested over a dozen drugs in two years.

Childhood leukemia survival rates improved from 15% to 80-90% primarily through better treatment regimens discovered via clinical trial networks across the US, Canada, and Europe, not just new drugs.

Market Failures and Innovative Funding Models

Advanced market commitments successfully created pneumococcal vaccines for African bacterial strains by having seven countries and the Gates Foundation guarantee payment per dose administered to children.

Priority vouchers allow companies developing orphan drugs to move other commercial drugs to the front of FDA review queues, creating commercial incentives for neglected diseases.

Gene editing treatments for sickle cell disease and blindness cost up to $3 million for one-time cures, creating affordability crises even when spread over lifetime treatment costs.

"5 to 7% of the population has a rare disease" - collectively representing millions of people, suggesting platform approaches targeting multiple rare diseases could unlock treatments at scale.

Three High-Leverage Reforms for Medical Progress

Make clinical trial participation easy by adding simple checkboxes to routine medical forms, allowing researchers to contact interested patients with matching conditions across the country.

Create federally funded or coalition-based clinical trials testing multiple drugs simultaneously using the same protocol, recruitment, and control groups instead of fragmenting efforts.

Establish secure platforms where researchers deposit trial data for reuse, enabling others to learn from past successes and failures instead of redundantly repeating failed approaches.